ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 13L

Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial

Jens Humrich1, Caroline von Spee-Mayer2, Elise Siegert3, Angelika Rose2, Martina Bertolo4, Philipp Enghard5, Falk Hiepe6, Tobias Alexander7, Eugen Feist8, Andreas Radbruch9, Gerd R. Burmester10 and Gabriela Riemekasten11, 1Department of Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, 2Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, 3Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, 4Department of Rheumatology, Charité – University Medicine Berlin, Berlin, Germany, 5Department of Nephrology, Charité – University Medicine Berlin, Berlin, Germany, 6Charité – Universitätsmedizin, Berlin, Germany, 7Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, 8Charité-Universitätsmedizin Berlin, Berlin, Germany, 9Deutsches Rheumaforschungszentrum, Berlin, Germany, 10Charité – University Medicine Berlin, Berlin, Germany, 11Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: October 19, 2016

Keywords: cytokines and regulatory cells, Immunotherapy, Late-Breaking 2016, SLE

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 15, 2016

Session Title: ACR Late-Breaking Poster Session

Session Type: ACR Late-breaking Abstract Session

Session Time: 9:00AM-11:00AM

Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies we have proven the significance of an acquired IL-2 deficiency and related Treg defects in the pathogenesis of systemic lupus erythematosus (SLE). Accordingly, we showed that compensation of IL-2 deficiency by low dose IL-2 therapy is capable to correct Treg defects in SLE patients.

Here, we conducted a combined phase I/IIa single center clinical trial (PRO-IMMUN; EudraCT-Number: 2013-001599-40; DRKS-ID: DRKS00004858) addressing the safety, tolerability, immunological responses and clinical efficacy of a subcutaneous low-dose IL-2 therapy in patients with refractory and active SLE.

Methods: 10 patients with active and refractory SLE (SLEDAI ≥ 6; at least two different immunosuppressive therapies) were enroled into the trial and 2 patients were treated „off-label“ with the same regimen. The therapeutic regimen consisted of four treatment cycles each with daily subcutaneous injections of recombinant human IL-2 (aldesleukin) at single doses of 0.75, 1.5 or 3.0 million IU on five consecutive days separated by washout-periods of 9-16 days and followed by a 9-week follow-up period. Cells from peripheral blood were analysed by flow cytometry at every study visit before the IL-2 injections and one day after the 5th IL-2 injection. The primary objective was to show an increase in the percentage of CD25hi cells among CD3+CD4+Foxp3+CD127lo Treg cells by at least 100% (2-fold) after the 4th treatment cycle compared to baseline. Safety and tolerability were evaluated descriptively. Secondary objectives included the clinical responses assessed by SLEDAI and changes in serological and other immunological parameters.

Results: All 12 patients showed an effective and cycle-dependent increase in the percentage of CD25hi cells among Treg (p<0.001). 10 patients showed a reduction in SLEDAI (83.3%, p<0.05) and 8 patients achieved a clinical response (66.7%) with a complete disappearance of clinical manifestations such as rash, arthritis, myositis and alopecia. Levels of complement were significantly increased after the treatment compared to baseline (p<0.05). However, we could not observe a reduction in levels of anti-dsDNA-Abs. Treatment-related adverse events were generally mild and transient.

Conclusion: Low-dose IL-2 therapy is capable to safely and selectively expand the Treg population and to decrease disease activity in patients with active and refractory SLE. This study provides the basis for larger and placebo-controlled clincial studies aiming to prove the efficacy of this novel biologic treatment strategy.


Disclosure: J. Humrich, None; C. von Spee-Mayer, None; E. Siegert, None; A. Rose, None; M. Bertolo, None; P. Enghard, None; F. Hiepe, None; T. Alexander, None; E. Feist, None; A. Radbruch, None; G. R. Burmester, AbbVie, Bristol-Myers Squibb, MedImmune, Merck, Pfizer, Roche, and UCB, 2,AbbVie, Bristol-Myers Squibb, MedImmune, Merck, Pfizer, Roche, and UCB, 5,AbbVie, Bristol-Myers Squibb, Merck, Pfizer, Roche, and UCB, 8; G. Riemekasten, None.

To cite this abstract in AMA style:

Humrich J, von Spee-Mayer C, Siegert E, Rose A, Bertolo M, Enghard P, Hiepe F, Alexander T, Feist E, Radbruch A, Burmester GR, Riemekasten G. Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/low-dose-il-2-therapy-in-refractory-sle-results-from-single-center-phase-iiia-clinical-trial/. Accessed December 7, 2019.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-dose-il-2-therapy-in-refractory-sle-results-from-single-center-phase-iiia-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.